US Patent 3,980,778: Diflorasone Diacetate Claims, Expiration, and Patent Landscape

US Patent 3,980,778 covers the corticosteroid compound diflorasone and, more commercially importantly, diflorasone diacetate in topical, systemic, parenteral, antibacterial, and antifungal compositions. The patent issued on September 14, 1976, and its ordinary 17-year patent term expired on September 14, 1993. It therefore provides no current U.S. patent barrier to generic diflorasone diacetate products. Current commercial protection depends on FDA regulatory exclusivity, trademarks, formulation or manufacturing patents filed later, and market-specific approvals rather than this patent.

What drug and active ingredient does US 3,980,778 cover?

The patent covers a fluorinated synthetic glucocorticoid commonly known as diflorasone and its 17,21-diacetate ester, diflorasone diacetate.

Chemical form	Relevance under the claims	Commercial role
Diflorasone, the 17,21-dihydroxy compound	Expressly claimed in claim 1	Parent corticosteroid
Diflorasone diacetate	Claimed in claims 2-12	Approved topical active ingredient
Diflorasone diacetate at 0.05%	Falls within the topical concentration range	Common marketed strength

Diflorasone diacetate is a high-potency topical corticosteroid used for inflammatory and pruritic dermatoses, including corticosteroid-responsive skin conditions. FDA labeling identifies topical dosage forms such as creams, ointments, and related preparations. [2]

The distinction between the two chemical forms is material. Claim 1 is directed to the non-esterified compound. Claims 2 through 12 principally cover the 17,21-diacetate ester.

What are the scope and limitations of each claim?

The claims divide into five groups: the chemical compound, topical products, systemic products, combination products, and specific antibacterial or antifungal combinations.

Claim 1: diflorasone compound

Claim 1 is a composition-of-matter claim to:

6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione.

This is the parent steroid structure. A product containing only the claimed parent compound would fall within the literal scope of claim 1 if the structural identity is established.

Claim 1 does not, on its face, require:

A particular dosage form
A pharmaceutical carrier
A therapeutic indication
A concentration
A route of administration
The 17,21-diacetate ester

The esterification difference matters. A product containing only diflorasone diacetate would not ordinarily infringe claim 1 literally because the acetate groups change the claimed chemical structure. Claims 2 through 12 address the diacetate form.

Claims 2 and 3: topical or local compositions and treatment methods

Claims 2 and 3 cover topical or local treatment of inflammation of skin or mucous membrane using diflorasone diacetate.

The principal limitations are:

Limitation	Scope
Active ingredient	Diflorasone diacetate
Concentration	About 0.001% w/w to about 1.0% w/w
Vehicle	Pharmaceutical carrier
Use	Inflammation of skin or mucous membrane
Administration	Topical or local application

A 0.05% cream, ointment, lotion, gel, or comparable topical preparation falls within the stated concentration range. The range is broad enough to include most conventional topical development strengths.

Claim 2 is a product claim. It requires the active ingredient, the specified concentration range, and a pharmaceutical carrier.

Claim 3 is a method claim. It requires the topical or local application of the covered concentration in association with a pharmaceutical carrier for treating inflammation.

The method claim does not require a particular disease. It is drafted around the broader category of inflammation of skin or mucous membrane.

Claims 4 through 6: systemic and parenteral administration

Claim 4 covers a therapeutic composition containing 0.1 to 25 mg of diflorasone diacetate per unit dosage form.

Claim 5 narrows claim 4 to parenteral administration and requires:

A sterile vehicle
Diflorasone diacetate at 0.01% to 10% w/v

Claim 6 covers systemic treatment using 0.1 to 25 mg of diflorasone diacetate with a pharmaceutical carrier.

These claims are materially broader in route than the currently recognized topical commercial use. They reach oral, injectable, or other systemic administration if the product satisfies the dosage and carrier limitations. The patent claims do not establish that a systemic diflorasone diacetate product received FDA approval.

From a modern product-screening perspective, claims 4 through 6 have limited blocking value because the patent term has expired and the covered systemic products do not create a current exclusivity right.

Claims 7 through 12: antibacterial and antifungal combinations

Claims 7 through 12 cover topical combinations containing diflorasone diacetate and antimicrobial agents.

Claim	Combination
7	Diflorasone diacetate plus an antibacterial agent
8	Diflorasone diacetate plus an antifungal agent
9	Diflorasone diacetate plus neomycin sulfate
10	Diflorasone diacetate plus an antibacterial and an antifungal agent
11	Diflorasone diacetate plus chloroxine
12	Diflorasone diacetate plus neomycin sulfate and chloroxine

Claims 9 and 12 are the narrowest and most commercially specific. They identify neomycin sulfate and chloroxine by name. The claims do not specify concentrations for those antimicrobial ingredients, which leaves formulation details to the broader requirements of the dependent claims and the disclosure.

The combination claims could have been relevant to products marketed for inflammatory dermatoses with suspected bacterial or fungal involvement. They do not create current patent risk because the underlying patent expired in 1993.

When did US Patent 3,980,778 expire?

US Patent 3,980,778 issued on September 14, 1976. For a U.S. patent subject to the pre-June 8, 1995 patent-term rules, the term was generally 17 years from issuance. The resulting expiration date was September 14, 1993. [1] [3]

Event	Date
U.S. patent issue	September 14, 1976
Ordinary patent term	17 years from issue
Expiration	September 14, 1993
Current enforceability	None

The patent predates the Uruguay Round Agreements Act transition rules. Its term was therefore not measured from the earliest effective U.S. filing date under the modern 20-year term.

No patent term extension or patent term adjustment could restore enforceability after expiration. Patent term extension under 35 U.S.C. § 156 applies to qualifying regulatory review delays, but the patent’s term ended decades ago. [3]

What patent protection remains for diflorasone diacetate?

US Patent 3,980,778 does not provide current protection. A present-day freedom-to-operate analysis must separate the expired active-ingredient patent from later patents directed to commercial products or manufacturing processes.

Potential later protection categories

Later patent activity, if any, would generally fall into these categories:

Formulation patents
These may cover a specific cream base, emulsion, ointment, gel, foam, lotion, penetration-enhancing system, or stability profile.
Manufacturing patents
These may cover synthesis, purification, crystallization, polymorph control, particle size, impurity reduction, or esterification steps.
Combination-product patents
These may cover diflorasone diacetate with an antimicrobial, keratolytic, moisturizer, barrier-repair agent, or other active ingredient.
Delivery-system patents
These may cover sprays, metered-dose products, transdermal systems, occlusive delivery, or enhanced dermal penetration.
Method-of-use patents
These may target a defined disease, treatment duration, patient population, dosing schedule, or reduced-adverse-effect regimen.
Container and device patents
These may protect a dispenser, applicator, tube, pump, or packaging configuration rather than the drug itself.

The existence of a later patent cannot be inferred from US 3,980,778 or from the supplied claims. The foundational compound and broad therapeutic concepts are no longer patent-protected through this patent.

What is the FDA and Orange Book status of diflorasone diacetate?

Diflorasone diacetate is an FDA-recognized topical corticosteroid active ingredient. Marketed products have included 0.05% strengths in cream and ointment dosage forms, including products associated with the Apexicon and Psorcon brands and generic equivalents. Product availability and marketing status can vary by manufacturer and dosage form. [2] [4]

The Orange Book analysis should be separated into three issues:

Issue	Assessment
Listed drug approval	Diflorasone diacetate has FDA-approved topical products
US 3,980,778 listing	Expired patent; no current blocking effect
Generic pathway	Abbreviated New Drug Application pathway may be available for qualifying products

A generic applicant generally must address listed patents and exclusivity associated with the reference product. A Paragraph IV certification is relevant only to an unexpired listed patent. An expired patent cannot block approval or launch, although an applicant may still need to address any later unexpired patents listed for the applicable reference product. [4] [5]

The patent at issue does not create current Paragraph IV exposure. It also does not create current pediatric, orphan, or new chemical entity exclusivity.

Are there Paragraph IV challenges or generic launch risks?

US Patent 3,980,778 cannot support a current Paragraph IV challenge because its term expired in 1993. A generic diflorasone diacetate applicant would not face a launch injunction based on this patent.

The relevant launch risks are instead product-specific:

Formulation and sameness risk

A generic applicant must establish pharmaceutical equivalence and bioequivalence or demonstrate the applicable FDA standard for a topical product. Topical corticosteroids can present complex bioequivalence issues because performance depends on:

Vehicle composition
Particle size
Drug release
Skin permeation
Emulsion structure
Rheology
Crystal form
Container closure
Preservative system

A formulation that uses a different vehicle may avoid a formulation patent but still require substantial FDA development work.

Later-patent risk

A later patent could create risk if it claims:

A particular 0.05% composition
A proprietary cream or ointment base
A combination with neomycin, chloroxine, or another antimicrobial
A specific manufacturing process
A delivery device
A defined method of treating a disease or patient subgroup

The expired compound patent does not eliminate those risks. It eliminates only the protection supplied by the 1976 patent and its claims.

Regulatory launch scenarios

Scenario	Patent position
Generic diflorasone diacetate using a conventional non-proprietary vehicle	No risk from US 3,980,778
Generic 0.05% cream matching the reference product	Main issues are FDA approval and any later listed patents
Diflorasone plus neomycin	No risk from expired claim 9, subject to later patents
Diflorasone plus neomycin and chloroxine	No risk from expired claim 12, subject to later patents
Injectable or systemic diflorasone diacetate	No risk from expired claims 4-6, but separate FDA development issues apply
New spray, foam, or enhanced-delivery product	Potential formulation, device, or method-of-use patent exposure

How strong was the patent estate for diflorasone diacetate?

The original patent had strong historical breadth because it combined:

A composition-of-matter claim to the parent steroid
Broad topical concentration coverage
Local-treatment method protection
Systemic dosage claims
Parenteral composition claims
Antibacterial and antifungal combinations
Named neomycin sulfate and chloroxine combinations

Its weakness today is temporal rather than substantive. Every claim is expired. The patent cannot be asserted against manufacture, sale, use, or importation occurring after expiration.

The estate also had a structural limitation: the claims did not uniformly cover every possible commercial feature. They did not expressly claim:

A specific cream base
A defined particle size
A particular polymorph
A specific container
A manufacturing process
A particular FDA-approved brand
A defined pharmacokinetic or dermal-delivery profile

Those gaps could have supported later patent filings, but they are not supplied by US 3,980,778.

What patent litigation and settlement issues affect the drug?

US Patent 3,980,778 cannot support current infringement litigation. Any historical litigation involving diflorasone diacetate, its brands, or generic products would have to be analyzed separately from the patent’s present legal status.

No settlement agreement can extend the term of an expired patent. A private license or settlement could allocate commercial rights during the patent term, but it cannot revive the statutory exclusionary right after September 14, 1993.

For current diligence, the relevant litigation questions are:

Whether a later formulation patent is listed for the relevant reference product
Whether an ANDA applicant made a Paragraph IV certification to a later patent
Whether the reference-product sponsor filed a patent-infringement action within the statutory period
Whether a settlement imposed a delayed generic-entry date
Whether a later patent covers the exact dosage form and vehicle under review

Those questions do not change the conclusion for US 3,980,778 itself.

How does diflorasone compare with competing topical corticosteroid patents?

Diflorasone diacetate competes with other potent or super-potent topical corticosteroids, including clobetasol propionate, betamethasone dipropionate, fluocinonide, halobetasol propionate, and desoximetasone.

Drug	General competitive position	Foundational compound patent status
Diflorasone diacetate	High-potency topical corticosteroid	Foundational patents expired
Clobetasol propionate	Very high-potency topical corticosteroid	Foundational patents expired
Betamethasone dipropionate	Potent topical corticosteroid	Foundational patents expired
Fluocinonide	Potent topical corticosteroid	Foundational patents expired
Halobetasol propionate	Very high-potency topical corticosteroid	Foundational patents expired
Desoximetasone	Potent topical corticosteroid	Foundational patents expired

Competition is therefore driven primarily by formulation performance, approved labeling, generic price, product availability, prescriber familiarity, and brand positioning. The active pharmaceutical ingredient is generally not protected by an enforceable foundational patent.

What geographic coverage did US Patent 3,980,778 provide?

The patent provided protection only in the United States. It did not directly protect diflorasone or diflorasone diacetate in Canada, Europe, Japan, or other jurisdictions.

Foreign protection would have required separate national or regional patent rights. Any corresponding foreign patent family members would have had their own filing dates, patent terms, maintenance requirements, and expiration dates. Expiration of the U.S. patent did not automatically determine the status of foreign rights.

For global licensing or launch planning, the U.S. patent is therefore a historical asset, not a current worldwide patent indicator.

Key Takeaways

US Patent 3,980,778 covers diflorasone and diflorasone diacetate.
Claims 2 and 3 cover topical or local diflorasone diacetate products at about 0.001% to 1.0% w/w.
Claims 4 through 6 cover unit-dose, parenteral, and systemic compositions and treatments.
Claims 7 through 12 cover antibacterial and antifungal combinations, including neomycin sulfate and chloroxine.
The patent issued September 14, 1976, and expired September 14, 1993.
It cannot support current infringement litigation, a launch injunction, or a Paragraph IV challenge.
Current risk must be assessed against later formulation, manufacturing, device, combination, and method-of-use patents.
FDA and Orange Book diligence must be conducted at the reference-product and dosage-form level.
Diflorasone diacetate competes in a largely off-patent topical corticosteroid market.

FAQs

Does US Patent 3,980,778 cover diflorasone diacetate cream at 0.05%?

Yes, claims 2 and 3 cover topical diflorasone diacetate compositions and treatment methods within about 0.001% to 1.0% w/w. A 0.05% product falls within that range, but the patent expired in 1993.

Does the patent cover diflorasone diacetate ointment?

Yes, the topical composition claims are not limited to a cream. An ointment or other topical carrier could fall within the claims if it contains the specified active ingredient and concentration.

Can an expired patent still be listed in the Orange Book?

An expired patent may remain in historical patent records, but it cannot create a current approval block or enforceable exclusionary right. Current patent relevance depends on unexpired patents listed for the applicable reference product.

Is diflorasone diacetate a biologic subject to biosimilar competition?

No. Diflorasone diacetate is a synthetic small-molecule corticosteroid. Generic competition proceeds through the applicable small-molecule drug pathway, generally an ANDA rather than a biosimilar application.

Are neomycin and chloroxine combination products still protected by claim 12?

No. Claim 12 expired with US Patent 3,980,778 on September 14, 1993. A later patent could protect a particular combination formulation or use, but claim 12 itself provides no current protection.

References

U.S. Patent and Trademark Office. (1976). US Patent No. 3,980,778, Diflorasone compounds and pharmaceutical compositions.
U.S. National Library of Medicine. (n.d.). DailyMed: Diflorasone diacetate topical products.
United States Code, 35 U.S.C. §§ 154, 156.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and patent certifications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	197216	⤷ Start Trial
Australia	468257	⤷ Start Trial
Australia	5257973	⤷ Start Trial
Belgium	796560	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 3,980,778

Summary for Patent: 3,980,778